Biodesix Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Public

  • Employees
  • 334

Employees

  • Stock Symbol
  • BDSX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $9.86
  • (As of Friday Closing)

Biodesix General Information

Description

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Contact Information

Website
www.biodesix.com
Formerly Known As
Elston Technologies
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 919 West Dillon Road
  • Louisville, CO 80027
  • United States
+1 (303)
Primary Industry
Diagnostic Equipment
Other Industries
Laboratory Services (Healthcare)
Biotechnology
Stock Exchange
NAS
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences, Oncology
Corporate Office
  • 919 West Dillon Road
  • Louisville, CO 80027
  • United States
+1 (303)

Biodesix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biodesix Stock Performance

As of 13-Nov-2026, Biodesix’s stock price is $9.86. Its current market cap is $110M with 11.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.86 $9.79 $5.26 - $31.97 $110M 11.1M 163K -$2.75

Biodesix Financials Summary

As of 30-Sep-2026, Biodesix has a trailing 12-month revenue of $105M.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 356,540 110,423 253,115 197,384
Revenue 105,212 88,499 71,323 49,087
EBITDA (13,441) (21,948) (29,217) (37,103)
Net Income (27,078) (35,265) (42,931) (52,146)
Total Assets 93,944 87,476 97,244 99,096
Total Debt 72,440 72,854 61,976 60,691
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biodesix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biodesix‘s full profile, request access.

Request a free trial

Biodesix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Biodesix‘s full profile, request access.

Request a free trial

Biodesix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment
Diagnostic Equipment
Louisville, CO
334 As of 2025

South San Francisco, CA
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biodesix Competitors (27)

One of Biodesix’s 27 competitors is Veracyte, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Veracyte Formerly VC-backed South San Francisco, CA
Guardant Health Formerly VC-backed Palo Alto, CA
Exagen Formerly VC-backed Vista, CA
Myriad Genetics Corporation Salt Lake City, UT
Asuragen Formerly VC-backed Austin, TX
You’re viewing 5 of 27 competitors. Get the full list »

Biodesix Patents

  • 257

    Total Documents Applications and Grants

  • Total Patents Families

  • 149

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

Biodesix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4466728-A1 Sensitive and accurate feature values from deep maldi spectra Pending 21-Jan-2022
US-20250379043-A1 Sensitive and accurate feature values from deep maldi spectra Pending 21-Jan-2022
WO-2023141569-A1 Sensitive and accurate feature values from deep maldi spectra Inactive 21-Jan-2022
EP-4423134-A1 Antibodies targeting pulmonary nodule specific biomarkers and uses thereof Pending 29-Oct-2021
US-11542340-B1 Antibodies targeting pulmonary nodule specific biomarkers and uses thereof Active 29-Oct-2021 C07K16/2896
To view Biodesix’s complete patent history, request access »

Biodesix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biodesix Acquisitions (2)

Biodesix’s most recent deal was a Merger/Acquisition with Oncimmune (USA). The deal was made on 01-Nov-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Oncimmune (USA) 01-Nov-2019 Merger/Acquisition Diagnostic Equipment
Integrated Diagnostics 09-Jul-2018 Merger/Acquisition Diagnostic Equipment
To view Biodesix’s complete acquisitions history, request access »

Biodesix ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

21.1 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,585

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Biodesix’s complete esg history, request access »

Biodesix FAQs

  • When was Biodesix founded?

    Biodesix was founded in 2005.

  • Where is Biodesix headquartered?

    Biodesix is headquartered in Louisville, CO.

  • What is the size of Biodesix?

    Biodesix has 334 total employees.

  • What industry is Biodesix in?

    Biodesix’s primary industry is Diagnostic Equipment.

  • Is Biodesix a private or public company?

    Biodesix is a Public company.

  • What is Biodesix’s stock symbol?

    The ticker symbol for Biodesix is BDSX.

  • What is the current stock price of Biodesix?

    As of 13-Nov-2026 the stock price of Biodesix is $9.86.

  • What is the current market cap of Biodesix?

    The current market capitalization of Biodesix is $110M.

  • What is Biodesix’s current revenue?

    The trailing twelve month revenue for Biodesix is $105M.

  • Who are Biodesix’s competitors?

    Veracyte, Guardant Health, Exagen, Myriad Genetics, and Asuragen are some of the 27 competitors of Biodesix.

  • What is Biodesix’s annual earnings per share (EPS)?

    Biodesix’s EPS for 12 months was -$2.75.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process